Skip to content

Study · Non-randomized trial · 2011

6 results

Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G

Medical science monitor : international medical journal of experimental and clinical research1 Aug 2011Cited by 32 (Europe PMC)

PMID21804463 (opens in a new tab)PMCIDPMC3539612 (opens in a new tab)DOI10.12659/msm.881905 (opens in a new tab)PepBankPUB-21804463
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, procollagen type 1 N-terminal propeptide increased 127% during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, the bone formation marker increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseProcollagen type 1 N-terminal propeptide
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · 18 monthsAs given in this study (human).

    Measurements

    Procollagen type 1 N-terminal propeptide increase
    127%
    group A at 18 months (T18)

    Source sentences

    Summary
    Group A, at T18 procollagen type 1 N-terminal propeptide levels, increased 127%; bone alkaline phosphatase levels increased to 65%; N-telopeptide cross-links levels increased to 110%.
    2 context sentences
    Summary · context
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
    Summary · context
    Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, bone alkaline phosphatase increased to 65% during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, bone alkaline phosphatase increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone alkaline phosphatase
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · 18 monthsAs given in this study (human).

    Measurements

    Bone alkaline phosphatase increase
    65%
    group A at 18 months (T18)

    Source sentences

    Summary
    Group A, at T18 procollagen type 1 N-terminal propeptide levels, increased 127%; bone alkaline phosphatase levels increased to 65%; N-telopeptide cross-links levels increased to 110%.
    2 context sentences
    Summary · context
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
    Summary · context
    Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, N-telopeptide cross-links increased to 110% during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, N-telopeptide cross-links increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseN-telopeptide cross-links
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · 18 monthsAs given in this study (human).

    Measurements

    N-telopeptide cross-links increase
    110%
    group A at 18 months (T18)

    Source sentences

    Summary
    Group A, at T18 procollagen type 1 N-terminal propeptide levels, increased 127%; bone alkaline phosphatase levels increased to 65%; N-telopeptide cross-links levels increased to 110%.
    2 context sentences
    Summary · context
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
    Summary · context
    Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, lumbar bone mineral density increased to 12.4% during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, lumbar bone density increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar bone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · 18 monthsAs given in this study (human).

    Measurements

    Lumbar bone mineral density increase
    12.4%
    group A at 18 months (T18)

    Source sentences

    Summary
    After 18 months, lumbar bone mineral density increased to 12.4% and femoral bone mineral density increased to 5.2% in group A.
    2 context sentences
    Summary · context
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
    Summary · context
    Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, femoral bone mineral density increased to 5.2% during teriparatide treatment.

    In plain wordsIn women with severe osteoporosis, femoral bone density increased from baseline during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral bone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · 18 monthsAs given in this study (human).

    Measurements

    Femoral bone mineral density increase
    5.2%
    group A at 18 months (T18)

    Source sentences

    Summary
    After 18 months, lumbar bone mineral density increased to 12.4% and femoral bone mineral density increased to 5.2% in group A.
    2 context sentences
    Summary · context
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
    Summary · context
    Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with severe osteoporosis, one new vertebral fracture occurred with teriparatide (2.4%), versus six fractures with bisphosphonates (15.7%).

    In plain wordsIn women with severe osteoporosis, one new vertebral fracture occurred with teriparatide, compared with six fractures with bisphosphonates.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseNew vertebral fracture
    Study

    n: not reported in source

    Comparator
    Bisphosphonates
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · 18 monthsAs given in this study (human).

    Measurements

    New vertebral fracture rate
    2.4%
    teriparatide group A
    New vertebral fracture rate
    15.7%
    bisphosphonate group B

    Source sentences

    Summary
    Only a new vertebral fracture occurred in group A (2.4%), whereas 6 fractures occurred in group B (15.7%).
    2 context sentences
    Summary · context
    We studied the use of teriparatide in postmenopausal women with severe osteoporosis.
    Summary · context
    Group A was treated for 18 months with 20 µg/day of teriparatide. Group B was treated with bisphosphonates 70 mg/week. Every woman assumed 1 g of calcium and 800 IU of vitamin D3 daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.